
ABIOMED (ABMD) Earnings Dates & Reports
ABIOMED (ABMD) Most Recent Earnings
Report DateNov 1, 2022
Period EndingQ2 2023
Est. EPS$1.04
Actual EPS$1.30
EarningsBeat
ABIOMED (ABMD) Earnings
View the latest ABIOMED (ABMD) earnings report, listen to the earnings call, and analyze historical earnings performance with AI-powered insights.
Start investing in ABIOMED (ABMD)
Order type
Buy in
Order amount
Est. shares
0 shares
ABIOMED (ABMD) Earnings per Share (EPS) History
Signup for full accessBrowse free
ABIOMED (ABMD) Latest Earnings
The value each ABMD share was expected to gain vs. the value each share gained.
ABIOMED (ABMD) reported its most recent earnings on Nov 1, 2022 for Q2 2023, posting earnings per share (EPS) of $1.30. This exceeded analysts' expectations of $1.04 by 25.00%, marking a Beat.
For comparison, ABIOMED reported EPS of $1.03 in the same quarter last year.
The company is expected to announce its next earnings report on 11/01/2022, with analysts projecting an EPS of $0.
ABIOMED (ABMD) Earnings History
ABIOMED (ABMD) Earnings Related Price Changes
Earnings announcements may impact a stock’s price. This table highlights the ABIOMED’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.
Report date | Price 1D before | Price 1D after | Change |
---|---|---|---|
Aug 4, 2022 | — | — | — |
Apr 28, 2022 | — | — | — |
Feb 3, 2022 | — | — | — |
Oct 28, 2021 | — | — | — |
ABIOMED (ABMD) Earnings FAQs
ABIOMED (ABMD) last reported earnings on Nov 1, 2022 for Q2 2023, posting an EPS of $1.30, which Beat the estimate of $1.04 by 25.00%.
For Q2 2023, ABIOMED (ABMD) reported an EPS of $1.30, exceeding analysts' estimate of $1.04 by 25.00%.
For Q2 2023, ABIOMED (ABMD) Beat expectations with an actual EPS of $1.30 vs. an estimated EPS of $1.04.
Following the last earnings report on Nov 1, 2022, ABIOMED (ABMD)'s stock price moved — from — to —.
The next ABIOMED (ABMD) earnings call is scheduled for Nov. 1, 2022, where executives will discuss financial results and outlook.